Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Microtubules in Signaling01:22

Microtubules in Signaling

1.5K
The primary cilium, made up of microtubules, acts as antennae on the cell surfaces for relaying external stimuli into the cells. These fine hair-like structures are present, generally one per cell. These are non-motile cilia in a 9+0 microtubules arrangement, where the central pair of microtubules are absent. The primary cilia arise from the basal body embedded in the cell membrane. Intraflagellar transport (IFT) carries requisite proteins from the cytoplasm to the cilium because the primary...
1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Setting.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Ictal semiology in precuneus seizures: A systematic review.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Mosaic variegated aneuploidy as a novel feature in patients with Mulibrey nanism and <i>TRIM37</i> variants.

Journal of medical genetics·2026
Same author

Proteome profiling of cerebrospinal fluid-derived extracellular vesicles reveals potential biomarkers for drug-resistant epilepsy.

Clinical proteomics·2025
Same author

Optical genome mapping identifies a balanced inversion disrupting DMD in a patient with Duchenne muscular dystrophy.

Molecular cytogenetics·2025
Same author

Response to Gruzin et al.

Genetics in medicine : official journal of the American College of Medical Genetics·2025

Related Experiment Video

Updated: May 6, 2026

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin
08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

2.2K

[Tuberous sclerosis].

Liisa Metsähonkala1, Leena Valanne, Anna-Kaisa Anttonen

  • 1HYKS, konsultaatio ja epilepsiaklinikka, lastenneurologian klinikkaryhmä.

Duodecim; Laaketieteellinen Aikakauskirja
|October 29, 2013
PubMed
Summary

Tuberous sclerosis is a genetic disorder causing benign tumors in organs like the skin, kidneys, and brain. Emerging treatments, including rapamycin, can now effectively suppress the growth of these tumors.

Area of Science:

  • Genetics
  • Oncology
  • Neurology

Context:

  • Tuberous sclerosis is a rare, autosomal dominant genetic disorder.
  • Characterized by the development of benign tumors (hamartomas) in multiple organs.
  • Tumor growth and organ dysfunction significantly impact patient morbidity.

Purpose:

  • To provide an overview of tuberous sclerosis, its genetic basis, and clinical manifestations.
  • To highlight the evolving treatment landscape for growing tumors associated with the condition.

Summary:

  • Tuberous sclerosis results from inactivating mutations in tumor suppressor genes (TSC1 or TSC2).
  • Affected organs include the skin, kidneys, heart, and central nervous system.
  • While tumors are typically benign, their growth can impair vital organ function.

More Related Videos

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

4.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K

Related Experiment Videos

Last Updated: May 6, 2026

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin
08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

2.2K
Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

4.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K

Impact:

  • Rapamycin and its analogs represent a significant therapeutic advancement.
  • These drugs offer a targeted approach to suppress tumor growth in tuberous sclerosis.
  • This pharmacological intervention is transforming the management of symptomatic tumors.